Breaking News Instant updates and real-time market news.

DRRX

Durect

$0.86

0.1336 (18.46%)

, GILD

Gilead

$64.87

-0.17 (-0.26%)

11:05
07/22/19
07/22
11:05
07/22/19
11:05

Gilead pact offers validation to Durect technology, says H.C. Wainwright

After Durect (DRRX) announced the "positive surprise" that Gilead Sciences (GILD) has licensed exclusive worldwide rights to use the company's SABER technology for HIV and hepatitis B virus development, H.C. Wainwright analyst Ed Arce said he believes this collaboration provides "substantial validation" to the SABER platform. The deal economics also provide Durect with a cash runway and flexibility, said Arce, who thinks other SABER deals could be coming. He keeps a Buy rating and $3.50 price target on Durect shares.

DRRX

Durect

$0.86

0.1336 (18.46%)

GILD

Gilead

$64.87

-0.17 (-0.26%)

  • 22

    Jul

  • 30

    Jul

  • 07

    Aug

  • 09

    Sep

DRRX Durect
$0.86

0.1336 (18.46%)

GILD Gilead
$64.87

-0.17 (-0.26%)

07/15/19
JEFF
07/15/19
NO CHANGE
Target $95
JEFF
Buy
Gilead deal with Galapagos 'smart and financially savvy,' says Jefferies
Gilead Sciences (GILD) will significantly expand its pipeline in a "smart and financially savvy" expanded partnership deal with Galapagos (GLPG), Jefferies analyst Michael Yee tells investors in a research note. Gilead essentially gained options on everything in Galapagos' pipeline without having to acquire the company full out, says the analyst. He likes the deal and thinks shares of Gilead will move higher as the Street's outlook continues to improve. Yee keeps a Buy rating on Gilead with a $95 price target.
07/15/19
STFL
07/15/19
NO CHANGE
Target $188
STFL
Buy
Galapagos price target raised to $188 from $121 at Stifel
Stifel analyst Adam Walsh raised his price target on Galapagos (GLPG) to $188 from $121 after the company announced a 10-year global research and development collaboration with Gilead (GILD), calling the collaboration "a win-win to both companies." The deal, which he thinks will keep Gilead and likely other buyers from acquiring Galapagos in the next 10 years, gives the latter a deep cash position and support to expand and accelerate its research and clinical programs while it is able to maintain its "unique culture, R&D platform and proven leadership," according to Walsh, who keeps a Buy rating on Galapagos shares.
07/15/19
07/15/19
DOWNGRADE

Market Perform
Galapagos downgraded to Market Perform after Gilead deal at Raymond James
As previously reported, Raymond James analyst Dane Leone downgraded Galapagos (GLPG) to Market Perform from Strong Buy after the company and Gilead (GILD) announced a major expansion of the current collaboration agreement and partnership between the two companies. The analyst believes Galapagos' stock has now fully realized his price target by achieving his core investment thesis. He retains a positive viewpoint of Galapagos within the context of the relationship expansion with Gilead, but will be watching for how key 2020 value drivers develop over the course of the second half of 2019.
07/18/19
PIPR
07/18/19
NO CHANGE
Target $10
PIPR
Overweight
Spring Bank research agreement with NIAID 'smart,' says Piper Jaffray
Piper Jaffray analyst Edward Tenthoff notes that Spring Bank (SBPH) entered into a research agreement with the National Institute of Allergy and Infectious Diseases, or NIAID, to study preclinical HBV antisense oligonucleotides. With the recent Arrowhead (ARWR) partnership with Janssen (JNJ), the analyst sees this as a "smart development program" building on Spring Bank's HBV expertise. Tenthoff also notes that Spring Bank is conducting the Phase IIb CATALYST 1 and 2 trials of 400mg inarigivir monotherapy/combination with Vemlidy in naive and suppressed HBV patients with preliminary data in the second quarter of 2020, while partner Gilead (GILD) is conducting a Phase II study of inarigivir plus Vemlidy in naive and suppressed HBV patients with initial data likely at AASLD in November. He reiterates an Overweight rating and $10 price target on Spring Bank's shares.

TODAY'S FREE FLY STORIES

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.